Vicki Goodman

6.8k total citations · 1 hit paper
24 papers, 2.3k citations indexed

About

Vicki Goodman is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Vicki Goodman has authored 24 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Molecular Biology and 6 papers in Organic Chemistry. Recurrent topics in Vicki Goodman's work include Melanoma and MAPK Pathways (10 papers), Colorectal Cancer Treatments and Studies (5 papers) and Renal cell carcinoma treatment (4 papers). Vicki Goodman is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Colorectal Cancer Treatments and Studies (5 papers) and Renal cell carcinoma treatment (4 papers). Vicki Goodman collaborates with scholars based in United States, Australia and Germany. Vicki Goodman's co-authors include George J. Brewer, Sofía D. Merajver, Robert Justice, Richard Pazdur, David E. Morse, S. Leigh Verbois, Ramzi Dagher, Edwin P. Rock, Jogarao Gobburu and Anne O’Hagan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Vicki Goodman

24 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

2007 407 citations Vicki Goodman, Edwin P. Rock et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vicki Goodman United States	20	1.2k	1.1k	583	432	242	24	2.3k
Heike Richly Germany	20	1.2k 1.0×	1.1k 1.0×	736 1.3×	380 0.9×	184 0.8×	56	2.4k
Kevin D. Courtney United States	22	682 0.6×	1.6k 1.4×	865 1.5×	754 1.7×	232 1.0×	68	2.9k
Steven D. Reich United States	26	787 0.7×	1.0k 0.9×	532 0.9×	353 0.8×	261 1.1×	73	2.3k
Scott N. Holden United States	23	2.2k 1.9×	1.3k 1.2×	860 1.5×	424 1.0×	195 0.8×	44	3.7k
Tracy Curley United States	24	1.1k 0.9×	1.7k 1.5×	1.3k 2.2×	395 0.9×	214 0.9×	51	3.3k
David Lebwohl United States	18	1.1k 0.9×	1.8k 1.6×	390 0.7×	360 0.8×	562 2.3×	31	3.2k
Linda Janisch United States	23	2.1k 1.8×	1.7k 1.6×	738 1.3×	400 0.9×	104 0.4×	68	3.6k
L. Austin Doyle United States	27	881 0.7×	1.1k 0.9×	850 1.5×	398 0.9×	116 0.5×	71	2.2k
Yazdi K. Pithavala United States	25	1.1k 0.9×	1.2k 1.0×	1.2k 2.1×	581 1.3×	213 0.9×	65	2.5k
Amna Ibrahim United States	26	1.7k 1.4×	744 0.7×	1.1k 1.8×	457 1.1×	109 0.5×	58	2.9k

Countries citing papers authored by Vicki Goodman

Since Specialization

Citations

This map shows the geographic impact of Vicki Goodman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicki Goodman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicki Goodman more than expected).

Fields of papers citing papers by Vicki Goodman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicki Goodman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicki Goodman. The network helps show where Vicki Goodman may publish in the future.

Co-authorship network of co-authors of Vicki Goodman

This figure shows the co-authorship network connecting the top 25 collaborators of Vicki Goodman. A scholar is included among the top collaborators of Vicki Goodman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicki Goodman. Vicki Goodman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Zhao, Xiaochen, Jun Shen, Vijay Ivaturi, et al.. (2020). Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. Annals of Oncology. 31(2). 302–309. 52 indexed citations

2.

Zhao, Xiaochen, Vijay Ivaturi, Mathangi Gopalakrishnan, et al.. (2017). Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. Cancer Research. 77(13_Supplement). CT101–CT101. 16 indexed citations

3.

Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations

4.

Ouellet, Danièle, Ekaterina Gibiansky, Anne O’Hagan, et al.. (2014). Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. The Journal of Clinical Pharmacology. 54(6). 696–706. 57 indexed citations

5.

Grob, Jean‐Jacques, Mayur M. Amonkar, Salvador Martín‐Algarra, et al.. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology. 25(7). 1428–1436. 37 indexed citations

6.

Falchook, Gerald S., Michael Millward, David S. Hong, et al.. (2014). BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer. Thyroid. 25(1). 71–77. 169 indexed citations

7.

Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations

8.

Johnston, Stephen, Henry Gómez, Salomon M. Stemmer, et al.. (2013). A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Research and Treatment. 137(3). 755–766. 33 indexed citations

9.

Planchard, David, Julien Mazières, Gregory J. Riely, et al.. (2013). Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 31(15_suppl). 8009–8009. 76 indexed citations

10.

Hong, David S., Luis M. Vence, Gerald S. Falchook, et al.. (2012). BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. Clinical Cancer Research. 18(8). 2326–2335. 82 indexed citations

11.

Kirkwood, John M., Georgina V. Long, Uwe Trefzer, et al.. (2012). BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. Journal of Clinical Oncology. 30(15_suppl). 8501–8501. 22 indexed citations

12.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(15_suppl). LBA8500–LBA8500. 35 indexed citations

13.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(18_suppl). LBA8500–LBA8500. 25 indexed citations

14.

Xu, Chun‐Fang, Vicki Goodman, Zhengyu Xue, et al.. (2010). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of Hepatology. 54(6). 1237–1243. 41 indexed citations

15.

Brave, Michael H., Vicki Goodman, Edvardas Kaminskas, et al.. (2008). Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate. Clinical Cancer Research. 14(2). 352–359. 190 indexed citations

16.

Slamon, Dennis J., Henry Gómez, Fairooz F. Kabbinavar, et al.. (2008). Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1016–1016. 70 indexed citations

17.

Rock, Edwin P., Vicki Goodman, S. Leigh Verbois, et al.. (2007). Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma. The Oncologist. 12(1). 107–113. 207 indexed citations

18.

Goodman, Vicki, George J. Brewer, & Sofía D. Merajver. (2005). Control of Copper Status for Cancer Therapy. Current Cancer Drug Targets. 5(7). 543–549. 57 indexed citations

19.

Goodman, Vicki, George J. Brewer, & Sofía D. Merajver. (2004). Copper deficiency as an anti-cancer strategy.. Endocrine Related Cancer. 11(2). 255–263. 137 indexed citations

20.

Brédart, Anne, et al.. (1996). An international study for the development and validation of a comprehensive assessment of satisfaction with care in a cancer patients population (CASC). Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 5. 8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact